Phase 3 trial in 517 adults with severe chronic alopecia areata: at week 24, SALT score ≤20 was reached by 33.0% on deuruxolitinib 8 mg BID and 38.3% on 12 mg BID vs 0.8% on placebo (P<.0001). Most drug-related adverse events were mild or moderate.
RCTn = 517
Tsianakas et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial